Press Releases

AVROBIO Announces the Appointment of Diana M. Escolar, M.D. as Chief Medical Officer

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 19, 2021-- AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced the appointment of Diana M. Escolar, M.D., FAAN, as chief medical officer. Dr.

Jan 19, 2021

AVROBIO to Present at the ICR Conference 2021

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 8, 2021-- AVROBIO , Inc. (NASDAQ: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay , president and CEO of AVROBIO , will present virtually at the ICR

Jan 08, 2021

AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 7, 2021-- AVROBIO , Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that the company has granted non-statutory stock options for the purchase of up to an

Jan 07, 2021



Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about AVROBIO’s research and pipeline.